文献速递血栓与止血

血浆脂联素水平与未来静脉血栓栓塞风险

Plasma levels of adiponectin and risk of future incident venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2026-07-31

基于Tromsø4调查的巢式病例对照研究纳入381例VTE病例和772名匹配对照,发现脂联素最高四分位组较最低组VTE风险降低,OR为0.69(95%CI 0.48-0.99);限定队列纳入后5年内分析关联更强,OR为0.40(95%CI 0.20-0.77)。

要点

  • 脂联素最高四分位组VTE风险低于最低组,OR 0.69(95%CI 0.48-0.99)。
  • 队列纳入后5年内,脂联素与VTE负关联更强,OR 0.40(95%CI 0.20-0.77)。
  • 调整BMI和CRP对风险估计影响较小。

核心结论

  • 高血浆脂联素水平与未来首次VTE风险降低相关,尤其在队列纳入后短期内。

研究设计与样本

  • 基于Tromsø4调查(1994/95-2007)的巢式病例对照研究,纳入381例VTE病例和772名年龄性别匹配对照。

主要发现

  • 整个研究期间,脂联素Q4 vs Q1的VTE OR为0.69(95%CI 0.48-0.99)。
  • 限定队列纳入后5年内,脂联素Q4 vs Q1的VTE OR为0.40(95%CI 0.20-0.77)。
  • 额外调整BMI和CRP对风险估计影响较小。

关键数值与推荐

  • 脂联素四分位基于对照组的性别特异性切点确定。

临床怎么用

  • 脂联素可能参与VTE发病机制,但尚不能作为临床风险分层指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adiponectin, a hormone-like protein primarily secreted by adipocytes, is typically decreased in obesity. Adiponectin has been shown to have antithrombotic properties through regulation of hemostatic factors in vitro. However, the association between adiponectin and venous thromboembolism (VTE) remains unclear. OBJECTIVES: To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE. METHODS: A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007). Adiponectin was measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across adiponectin quartiles (Q) determined in controls using sex-specific quartile cut-offs. To investigate short-term associations, time-restricted analysis was performed including VTE cases occurring up to 5 years after cohort inclusion. RESULTS: High adiponectin levels were associated with decreased VTE risk, with an OR of 0.69 (95% CI 0.48-0.99) for Q4 vs Q1 (reference) in age- and sex-adjusted analysis for the entire study period. The inverse association between adiponectin and VTE risk was stronger with analysis restricted to the first 5 years after cohort inclusion, with an OR of 0.40 (95% CI 0.20-0.77) for Q4 vs Q1. The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates. CONCLUSION: Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Onsaker AL, van Hylckama Vlieg A, Ueland T, et al. Plasma levels of adiponectin and risk of future incident venous thromboembolism. J Thromb Haemost. 2026. PMID: 42532277. doi:10.1016/j.jtha.2026.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。